Characterization of efflux transport of the PDE5 inhibitors, vardenafil and sildenafil.
Min-Koo Choi, Im-Sook Song
Index: J. Pharm. Pharmacol. 64(8) , 1074-83, (2012)
Full Text: HTML
Abstract
We aimed to characterize the efflux transport properties of vardenafil and sildenafil, and to compare the kinetics of these compounds via efflux transporters such as P-gp, BCRP and MRP2.We measured the basal-to-apical and apical-to-basal transport of vardenafil and sildenafil within the concentration range of 1-100 µm using MDCKII cells overexpressing P-gp, BCRP and MRP2, and Caco-2 cells.Vardenafil had a much greater basal-to-apical than apical-to-basal transport rate in MDCKII cells overexpressing P-gp, BCRP and MRP2. Sildenafil showed P-gp- and BCRP-mediated efflux transport, but did not seem to be pumped out via MRP2 transporters. Consequently, the absorptive transport of vardenafil and sildenafil in Caco-2 cells increased linearly over the concentration range of 1-100 µm, whereas the secretory transport of these drugs was saturable and inhibited by the presence of specific inhibitors of P-gp and BCRP. MK571, a representative MRP2 inhibitor, inhibited the basal-to-apical transport of vardenafil, but not of sildenafil.The involvement of P-gp, BCRP and MRP2 for vardenafil and the involvement of P-gp and BCRP for sildenafil in the secretory transport with linear absorptive transport may contribute to the limited intestinal absorption of these drugs.© 2012 The Authors. JPP © 2012 Royal Pharmaceutical Society.
Related Compounds
Related Articles:
2013-03-01
[Respir. Physiol. Neurobiol. 186(1) , 61-4, (2013)]
2013-01-01
[J. Sex. Med. 10(1) , 130-71, (2013)]
2013-02-01
[Eur. J. Clin. Pharmacol. 69(2) , 197-207, (2013)]
2012-11-30
[J. Biol. Chem. 287(49) , 41406-16, (2012)]
2012-11-01
[Endocrinology 153(11) , 5546-55, (2012)]